A 34-year-old man with a history of chronic cannabis use presented with an acute anterior ST-elevation myocardial infarction. Coronary angiography showed a large thrombus involving the left main and proximal left anterior descending arteries, with complete occlusion of the mid-LAD (TIMI 0 flow).

Given the extensive thrombus burden, clinicians treated him with intracoronary streptokinase followed by an intravenous dose, which produced significant thrombus resolution and restored TIMI II flow. He recovered without complication on dual antiplatelet therapy, a statin, and anticoagulation.

The authors propose that cannabis-associated thrombosis may involve several interacting pathways: a catecholamine surge causing tachycardia and vasospasm, endothelial dysfunction, and direct platelet activation through CB1 and CB2 receptors that increases thromboxane A2 and P-selectin expression.

Notably, angiography did not show significant atherosclerotic plaque, which is part of what makes this case distinct from a typical plaque-rupture heart attack and points instead toward a vasospastic and prothrombotic process.

This was a large-vessel occlusion in a young adult without significant angiographic atherosclerosis and, as described, without the conventional cardiovascular risk factors that typically prompt an aggressive workup in older patients.

That combination, chronic cannabis use plus an unexplained large thrombus burden, is the pattern the authors want emergency and primary care clinicians to recognize.

A single case report has no control group, no denominator, and no way to quantify how often this occurs among the much larger population of people who use cannabis without any cardiac event. It cannot separate the effect of cannabis from other unmeasured factors.

The report does not describe THC potency, route of administration, or co-use of tobacco, alcohol, or stimulants in detail sufficient to rule out contributing exposures. Case reports are hypothesis-generating, not hypothesis-confirming.

This case is a reasonable prompt to ask about cannabis use, frequency, and route of use when a young patient presents with acute coronary syndrome and no conventional risk factors, and to counsel patients with existing cardiovascular disease or risk factors about a plausible prothrombotic pathway.

It is not a reasonable basis for telling all cannabis users they are at high risk of a heart attack. The honest clinical message is a specific one: an uncommon but real and mechanistically plausible cardiovascular risk exists, and it deserves the same clinical curiosity as any other unexplained thrombotic event.

This case joins a small but real body of case reports and cohort-level safety signals connecting cannabis use to adverse cardiovascular events, including prior CED coverage of a Wellens syndrome case and cohort data on heart attack risk among cannabis users.

None of these individually prove causation, but taken together they support treating cannabis cardiovascular safety as a genuine, evolving clinical question rather than a settled non-issue, particularly as THC potency in commercial products has risen.

I take cardiovascular case reports like this one seriously without overreacting to them. A single case does not change how I counsel most patients, but it does change what questions I ask when a young, otherwise low-risk patient shows up with an unexplained thrombotic event.

For patients already living with cardiovascular disease or significant risk factors, this is one more reason I discuss route of administration, frequency, and product potency as part of a broader cardiovascular safety conversation, not as a reason to categorically rule cannabis out for every patient.

Four questions to ask before summarizing this case